Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review.
Michael J GrantPaul StockhammerMatthew R AustinZsuzsanna NemethDaniel P Petrylak
Published in: Bladder cancer (Amsterdam, Netherlands) (2024)
In addition to enfortumab vedotin and sacituzumab govitecan, various HER2-targeted antibody drug conjugates and ADC-anti-PD-1 combination regimens have demonstrated efficacy in clinical trials and are poised for clinical advancement.